The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Launched by JIANGXI PROVINCIAL CANCER HOSPITAL · Dec 25, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well patients with locally advanced nasopharyngeal carcinoma (NPC) respond to a specific type of chemotherapy treatment. The researchers want to find out if the amount of cancer that disappears after just one cycle of this treatment can help predict how well patients will do in the long run. They will also look at changes in the immune system, specifically how immune cells gather in the tumor area after treatment.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of locally advanced NPC. You should also be in reasonably good health to follow the study requirements. Participants will receive the chemotherapy and then have their progress monitored through scheduled visits and exams. This study is currently recruiting and aims to better understand the disease to improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ability to sign informed consent
• • 2. Age \> 18 years at time of study entry
• • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (amend based on specific study)
• • 4. Histological confirmation of NPC (regardless if EBER positive or negative)
• • 5. Locally advanced NPC, UICC stage III-IVa
• • 6. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
• Exclusion Criteria:
• • 1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
• • 2. Distant metastases
• • 3. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, radiotherapy, biologic therapy, tumour embolization, monoclonal antibodies) of the locally advanced NPC.
• • 4. History of another primary malignancy
• • 5. Female patients who are pregnant
• • 6. Known allergy or hypersensitivity to any drugs
• • 7. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.